Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
USD3.45
-0.71 (-17.07%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
One Research Court 20850
Gaithersburg, MD, US
Gaithersburg, MD, US
CEO
Christopher Robert Cooper
Website
shuttlepharma.com
IPO
2022-08-31
CIK 1757499 ISIN US8256935003
Description
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.45
-0.71 (-17.07%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
846.0K
Beta
1.22
Float Shares
987.1K
Free Float %
92.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.03% | +4.03% | -34.73% | -38.35% | -65.32% | -63.01% | -87.15% | -99.69% | -99.99% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.45
DCF (Levered)
0.06
-98.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-9.43
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+99.2% ★ Q1'26: +42.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-541.3% Q1'26: -359.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-84.1% ★ Q1'26: +23.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.02× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
171.1K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+171,054
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-06 | Liang Yuying | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-12 | Pathigoda Arachchige Sachin Eranga | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-09-12 | Liriano Angel | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-09-08 | Chambers Adam V | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-08-08 | Tung Joseph | Director | A-Award | A | Restricted Stock Unit | 29,240 | 0.00 | — | 29,240 | D | ↗ |
| 2025-08-08 | Scorsis George | Director | A-Award | A | Restricted Stock Unit | 29,240 | 0.00 | — | 29,240 | D | ↗ |
| 2025-08-08 | Richards Steven M | Director | A-Award | A | Restricted Stock Unit | 29,240 | 0.00 | — | 29,240 | D | ↗ |
| 2025-08-08 | Nabyt Oleh | Director | A-Award | A | Restricted Stock Unit | 29,240 | 0.00 | — | 29,240 | D | ↗ |
| 2025-08-08 | Lorber Timothy J. | Officer | A-Award | A | Restricted Stock Unit | 24,854 | 0.00 | — | 24,854 | D | ↗ |
| 2025-03-11 | Cooper Chris | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-28 | Tung Joseph | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 184,162 | D | ↗ |
| 2025-02-28 | Scorsis George | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 184,162 | D | ↗ |
| 2025-02-28 | Nabyt Oleh | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 184,162 | D | ↗ |
| 2024-12-31 | Schafer Joshua | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | Richards Steven M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | Brown Milton | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | Lorber Timothy J. | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 227,635 | — | ↗ |
| 2024-05-01 | Jung Mira | Officer | A-Award | D | CLASS A COMMON STOCK | 598 | 11.28 | 6.7K | 135,715 | D | ↗ |
| 2024-03-08 | Vander Hoek Michael | Officer | A-Award | A | COMMON STOCK | 100,000 | 0.00 | — | 103,852 | — | ↗ |
| 2023-12-13 | Jacobs Bette | Director | S-Sale | D | Common Stock | 4,157 | 0.46 | 1.9K | 27,064 | — | ↗ |
| 2023-12-13 | Brown Milton | Director | S-Sale | D | Common Stock | 2,921 | 0.46 | 1.4K | 1,094,610 | — | ↗ |
| 2023-08-14 | Dritschilo Anatoly | Director / Officer / 10% Owner | G-Gift | A | COMMON STOCK | 2,100,000 | 0.00 | — | 2,100,000 | — | ↗ |
| 2023-02-15 | Brown Milton | Director | A-Award | A | Stock Options | 25,000 | 1.92 | 48.0K | 25,000 | — | ↗ |
| 2022-12-29 | Vander Hoek Michael | Officer | S-Sale | D | COMMON STOCK | 2,243 | 1.61 | 3.6K | 3,852 | — | ↗ |
| 2022-12-29 | Senanayake Chris | Director | S-Sale | D | COMMON STOCK | 1,626 | 1.61 | 2.6K | 2,791 | — | ↗ |
| 2022-12-29 | Richards Steven M | Director | S-Sale | D | COMMON STOCK | 995 | 1.61 | 1.6K | 1,707 | — | ↗ |
| 2022-12-29 | Rich Tyvin | Officer | S-Sale | D | COMMON STOCK | 1,414 | 1.61 | 2.3K | 2,429 | — | ↗ |
| 2022-12-29 | Jung Mira | Officer | S-Sale | D | CLASS A COMMON STOCK | 328 | 1.61 | 526.44 | 1,071,388 | — | ↗ |
| 2022-12-29 | Jacobs Bette | Director | S-Sale | D | CLASS A COMMON STOCK | 4,366 | 1.61 | 7.0K | 31,221 | — | ↗ |
| 2022-12-29 | Dritschilo Peter | Officer | S-Sale | D | COMMON STOCK | 3,820 | 1.61 | 6.1K | 6,560 | — | ↗ |
| 2022-12-29 | Dritschilo Anatoly | Officer | S-Sale | D | COMMON STOCK | 8,372 | 1.61 | 13.4K | 1,085,200 | — | ↗ |
| 2022-12-29 | Brown Milton | Director | S-Sale | D | COMMON STOCK | 995 | 1.61 | 1.6K | 1,072,531 | — | ↗ |
| 2022-12-29 | Adkins William | Director | S-Sale | D | COMMON STOCK | 995 | 1.61 | 1.6K | 184,071 | — | ↗ |
| 2022-10-28 | Jacobs Bette | Director | — | D | COMMON STOCK | 0 | 0.00 | — | 35,587 | — | ↗ |
| 2022-09-02 | Adkins William | Director | J-Other | A | WARRANTS (right to buy) | 138,889 | 0.00 | — | 138,889 | — | ↗ |
| 2022-08-29 | Vander Hoek Michael | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 6,095 | — | ↗ |
| 2022-08-29 | Senanayake Chris | Director | — | D | COMMON STOCK | 0 | 0.00 | — | 3,843 | — | ↗ |
| 2022-08-29 | Schafer Joshua | Director | — | D | COMMON STOCK | 0 | 0.00 | — | 2,702 | — | ↗ |
| 2022-08-29 | Richards Steven M | Director | — | D | COMMON STOCK | 0 | 0.00 | — | 2,702 | — | ↗ |
| 2022-08-29 | Rich Tyvin | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 3,843 | — | ↗ |
| 2022-08-29 | Jung Mira | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 1,071,716 | — | ↗ |
| 2022-08-29 | Dritschilo Peter | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 10,380 | — | ↗ |
| 2022-08-29 | Dritschilo Anatoly | Director / Officer / 10% Owner | — | I | COMMON STOCK | 0 | 0.00 | — | 3,204,407 | — | ↗ |
| 2022-08-29 | Brown Milton | Director | — | D | COMMON STOCK | 0 | 0.00 | — | 1,073,526 | — | ↗ |
| 2022-08-29 | Adkins William | Director | — | D | COMMON STOCK | 0 | 0.00 | — | 280,480 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.07M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Anatoly Dritschilo M.D., former CEO | 109.5K | — | 224.6K | — | — | — | 334.2K | 67.22% | ↗ |
| 2 | 2025 | Timothy J. Lorber former CFO | 222.1K | — | 51.2K | — | — | — | 273.2K | 18.72% | ↗ |
| 3 | 2025 | Christopher Cooper CEO | 193.5K | — | — | — | — | — | 193.5K | 0.00% | ↗ |
| 4 | 2025 | Peter Dritschilo, former President and former COO | 147.7K | — | — | — | — | — | 147.7K | 0.00% | ↗ |
| 5 | 2024 | Anatoly Dritschilo M.D., CEO | 274.0K | — | — | — | — | — | 274.0K | 0.00% | ↗ |
| 6 | 2024 | Anatoly Dritschilo M.D., former CEO | 274.0K | — | — | — | — | — | 274.0K | 0.00% | ↗ |
| 7 | 2024 | Michael Vander Hoek, VP, CFO | 228.0K | — | 41.8K | — | — | — | 269.8K | 15.51% | ↗ |
| 8 | 2024 | Peter Dritschilo, President and COO | 236.0K | — | — | — | — | — | 236.0K | 0.00% | ↗ |
| 9 | 2024 | Peter Dritschilo, former President and former COO | 236.0K | — | — | — | — | — | 236.0K | 0.00% | ↗ |
| 10 | 2024 | Tyvin Rich, Chief Medical Officer | 218.0K | — | — | — | — | — | 218.0K | 0.00% | ↗ |
| 11 | 2024 | Timothy J. Lorber CFO | 97.6K | — | 100.0K | — | — | — | 197.6K | 50.60% | ↗ |
| 12 | 2024 | Timothy J. Lorber former CFO | 97.6K | — | 100.0K | — | — | — | 197.6K | 50.60% | ↗ |
| 13 | 2023 | Anatoly Dritschilo M.D., CEO | 287.2K | 112.0K | — | — | — | — | 399.2K | 0.00% | ↗ |
| 14 | 2023 | Peter Dritschilo, President and COO | 242.0K | 72.0K | — | — | — | — | 314.0K | 0.00% | ↗ |
| 15 | 2023 | Michael Vander Hoek, CFO, VP | 230.5K | 72.0K | — | — | — | — | 302.5K | 0.00% | ↗ |
| 16 | 2023 | Michael Vander Hoek, VP, CFO | 230.5K | 72.0K | — | — | — | — | 302.5K | 0.00% | ↗ |
| 17 | 2023 | Tyvin Rich, Chief Medical Officer | 220.2K | 43.0K | — | — | — | — | 263.2K | 0.00% | ↗ |
| 18 | 2022 | Anatoly Dritschilo M.D., CEO | 97.3K | — | 171.7K | — | — | — | 268.9K | 63.84% | ↗ |
| 19 | 2022 | Peter Dritschilo, President and COO | 100.3K | — | 78.3K | — | — | — | 178.6K | 43.85% | ↗ |
| 20 | 2022 | Michael Vander Hoek, CFO, VP | 82.8K | — | 46.0K | — | — | — | 128.8K | 35.72% | ↗ |
| 21 | 2022 | Tyvin Rich, Chief Medical Officer | 67.1K | — | 29.0K | — | — | — | 96.1K | 30.18% | ↗ |
| 22 | 2021 | Anatoly Dritschilo M.D., CEO | 18.8K | — | 171.7K | — | — | — | 190.5K | 90.12% | ↗ |
| 23 | 2021 | Peter Dritschilo, President and COO | 31.5K | — | 78.3K | — | — | — | 109.9K | 71.30% | ↗ |
| 24 | 2021 | Michael Vander Hoek, CFO, VP | 18.3K | — | 46.0K | — | — | — | 64.3K | 71.50% | ↗ |
| 25 | 2021 | Tyvin Rich, Chief Medical Officer | — | — | 29.0K | — | — | — | 29.0K | 100.00% | ↗ |
| 26 | 2021 | Anatoly Dritschilo, MD, CEO | 18.8K | — | — | — | — | — | 18.8K | 0.00% | ↗ |
| 27 | 2020 | Anatoly Dritschilo, MD, CEO | 35.1K | — | — | — | — | — | 35.1K | 0.00% | ↗ |
| 28 | 2020 | Peter Dritschilo, President and COO | 24.0K | — | — | — | — | — | 24.0K | 0.00% | ↗ |
| 29 | 2020 | Michael Vander Hoek, CFO, VP | 17.5K | — | — | — | — | — | 17.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Vander Hoek | Vice President for Operations and Regulatory | 506.6K | male |
| Christopher Robert Cooper | Interim CEO & Director | 240.0K | male |
| Tyvin A. Rich | Chief Clinical Officer & Chief Medical Officer | 218.0K | — |
| Yuying Liang | Chief Financial Officer | 177.5K | female |
| Milton Brown | Co-Founder | 4.2K | — |
| Mira Jung | Co-Founder & Chief Scientific Officer for Biology | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SHPH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
